Catalent expert invited to share formulation development expertise at Aerosol School

Posted: 11 April 2012 | | No comments yet

Dr. Lei Mao, Project Director and Group Leader, R&D of Catalent Pharma Solutions to present…

Dr. Lei Mao, Project Director and Group Leader, R&D of Catalent Pharma Solutions at its RTP, Morrisville site, will present “Formulation consideration of inhaled products” and “ Formulation consideration of nasal spray products” at the Aerosol School, Hamilton, Canada on April 11-13, 2012.

Aerosol School is an annual event sponsored by the International Society Aerosols in Medicine (ISAM), McMaster University, St. Joseph’s Healthcare. The three-day course held at Firestone Research Aerosol Laboratory in Hamilton, Ontario, Canada provides an in-depth introduction around aerosol basics/definitions, aerosol drug delivery devices, formulation science, aerosol drug delivery modeling, aerosol quality control presented by inhalation experts from the pharmaceutical industry and universities as well as a hands-on training on inhalation and nasal spray product testing. This is the second year that a Catalent inhalation expert has been invited to share inhalation drug development expertise at the Aerosol School.

Catalent Pharma Solutions is the world’s #1 partner for drug development and formulation services. Catalent has the broad capabilities in inhaled drug development with integrated services for complete range of dosage forms: pMDI, DPI, nasal and nebules. For over 20 years, Catalent’s deep development expertise and effective program execution have accelerated inhalation drug development time to market.

Dr. Mao holds BPharm and PhD in pharmaceutical sciences and has over twenty years experience in the pharmaceutical industry, with substantial expertise and knowledge in pharmaceutical product development, in particular dry powder inhaler, metered dose inhaler, nebulizer and nasal product development. Before joining Catalent, Dr. Mao has held team leader positions and senior scientist positions at Vectura plc, UK; IVAX, UK; China State Food and Drug Administration (SFDA) and National Institutes of Pharmaceutical Research and Development, China. He is a named inventor of fourteen patents granted worldwide, has authored one book and over thirty publications in peer reviewed journals and conference proceedings.

To learn more about Catalent’s inhalation drug development and manufacturing capabilities, click here. To receive a copy of this presentation after the event, please visit us at

For more information on this event, please visit

Related organisations